Press release: APEIRON shareholders approve new group structure
invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline
Vienna, Austria, 26 April 2022. APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of its preclinical and clinical development activities and the creation of a new fully separate holding company, invIOs Holding AG.
